ETM
SUPN icon

Euclidean Technologies Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Euclidean Technologies Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,424
Closed -$208K – 86
2022
Q1 		$208K Buy
+6,424
New +$197K 0.19% 78

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Euclidean Technologies Management's SUPN Position: Q2 2022 in Review

Euclidean Technologies Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 6,424 shares — an estimated $208K sold.

Euclidean Technologies Management first reported a position in SUPN in Q1 2022 and held it in 1 quarter. The position peaked at $208K in Q1 2022. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

  • Euclidean Technologies Management reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Euclidean Technologies Management sold 6,424 Supernus Pharmaceuticals shares in Q2 2022, an estimated $208K.
  • Euclidean Technologies Management first reported a position in Supernus Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Euclidean Technologies Management's Supernus Pharmaceuticals position peaked at $208K in Q1 2022.
  • 225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on Euclidean Technologies Management's 13F filing for Q2 2022, filed 25 Jul 2022.